TN2009000214A1 - Manufacture process - Google Patents

Manufacture process

Info

Publication number
TN2009000214A1
TN2009000214A1 TNP2009000214A TN2009000214A TN2009000214A1 TN 2009000214 A1 TN2009000214 A1 TN 2009000214A1 TN P2009000214 A TNP2009000214 A TN P2009000214A TN 2009000214 A TN2009000214 A TN 2009000214A TN 2009000214 A1 TN2009000214 A1 TN 2009000214A1
Authority
TN
Tunisia
Prior art keywords
manufacture process
relates
present
containing phosphate
iron containing
Prior art date
Application number
TNP2009000214A
Other languages
English (en)
French (fr)
Inventor
Michael Ambuhl
Corine Gessier-Vial
Christa Hartmann
Daniel Kaufmann
Ernst Kusters
Ulrich Meier
Andreas Meyer
Nabila Sekkat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38983614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000214(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06126122A external-priority patent/EP1932807A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000214A1 publication Critical patent/TN2009000214A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/06—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group B01J20/04
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/223—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material containing metals, e.g. organo-metallic compounds, coordination complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/2803—Sorbents comprising a binder, e.g. for forming aggregated, agglomerated or granulated products
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G49/00—Compounds of iron
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G49/00—Compounds of iron
    • C01G49/0018—Mixed oxides or hydroxides
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G49/00—Compounds of iron
    • C01G49/02—Oxides; Hydroxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • External Artificial Organs (AREA)
TNP2009000214A 2006-12-14 2009-05-29 Manufacture process TN2009000214A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06126101 2006-12-14
EP06126122A EP1932807A1 (en) 2006-12-14 2006-12-14 Inorganic compounds
PCT/EP2007/063832 WO2008071747A1 (en) 2006-12-14 2007-12-12 Iron (iii)-carbohydrate based phosphate adsorbent

Publications (1)

Publication Number Publication Date
TN2009000214A1 true TN2009000214A1 (en) 2010-10-18

Family

ID=38983614

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000214A TN2009000214A1 (en) 2006-12-14 2009-05-29 Manufacture process

Country Status (23)

Country Link
US (2) US8252310B2 (enExample)
JP (1) JP5456969B2 (enExample)
KR (1) KR20090094820A (enExample)
AR (1) AR064301A1 (enExample)
AU (1) AU2007331482B2 (enExample)
BR (1) BRPI0720272A2 (enExample)
CA (1) CA2671828C (enExample)
CL (1) CL2007003606A1 (enExample)
EC (1) ECSP099410A (enExample)
ES (1) ES2526171T3 (enExample)
IL (1) IL198548A0 (enExample)
MA (1) MA30993B1 (enExample)
MX (1) MX2009006307A (enExample)
MY (1) MY151047A (enExample)
NO (1) NO342285B1 (enExample)
NZ (1) NZ576672A (enExample)
PE (1) PE20081381A1 (enExample)
PT (1) PT2319804E (enExample)
RU (1) RU2447933C2 (enExample)
SI (1) SI2319804T1 (enExample)
TN (1) TN2009000214A1 (enExample)
TW (1) TWI465239B (enExample)
WO (1) WO2008071747A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
TWI592159B (zh) 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
JP2009292119A (ja) 2008-06-09 2009-12-17 Alps Electric Co Ltd サーマルヘッド
CN102089075B (zh) * 2008-06-13 2013-04-24 诺瓦提斯公司 用于制备含铁的磷酸盐吸附剂的制备方法
GB0814326D0 (en) * 2008-08-05 2008-09-10 Medical Res Council Phosphate binding materials and their uses
AU2010276242B2 (en) 2009-07-21 2014-05-29 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
DE102011112898A1 (de) 2011-09-08 2013-03-14 Charité - Universitätsmedizin Berlin Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
EP2766183A4 (en) * 2011-10-13 2015-07-01 Vidasym Inc IRON FIBER COMPOSITION, PREPARATION THEREOF AND USES THEREOF
RU2496722C1 (ru) * 2012-04-10 2013-10-27 Леонид Асхатович Мазитов Способ очистки сточной воды от фосфатов
US9796792B2 (en) 2013-03-08 2017-10-24 Vidasym, Inc. Metal ion-functional fiber component complex compositions, preparation and uses thereof
US9339489B2 (en) * 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
EP3431141B1 (en) * 2013-03-15 2021-12-08 Aprecia Pharmaceuticals LLC Three-dimensional printing method
HRP20240720T1 (hr) * 2013-11-27 2024-09-13 Vifor Fresenius Medical Care Renal Pharma, Ltd. Farmaceutski pripravak, koji sadrži čestice fosfatnog veziva
WO2015198304A1 (en) 2014-06-22 2015-12-30 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
US9901918B2 (en) 2015-03-04 2018-02-27 Graver Technologies Llc Hybrid ion exchange material and method for making the same
CN105193844A (zh) * 2015-05-27 2015-12-30 合肥川迪医药技术有限公司 用于制备含δ-羟基氧化铁(多核)及其药物组合物的方法及在高磷血症领域中的应用
US10399076B2 (en) 2016-03-28 2019-09-03 Sulfurcycle Intellectual Property Holding Company Methods of producing ferrihydrite nanoparticle slurries, and systems and products employing the same
WO2020025552A1 (en) 2018-07-30 2020-02-06 Interquim, S.A. Process for preparing an adsorbent for phosphate in aqueous medium
US12329778B2 (en) 2020-01-16 2025-06-17 Vifor Fresenius Medical Care Renal Pharma Ltd Particles of a mixture of iron(III)-oxyhydroxide, sucrose and one or more starches, preferably of sucroferric oxyhydroxide
CN115317494B (zh) * 2022-07-22 2024-02-13 康瑞鑫(天津)药物研究院有限公司 高磷酸盐结合力的蔗糖氢氧化氧铁及其制备方法
WO2025096992A1 (en) * 2023-11-01 2025-05-08 Navinta, Llc Process for isolation of solid ferric derisomaltose

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2885393A (en) * 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3697502A (en) * 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
US4180567A (en) * 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
DE3026868C2 (de) * 1980-07-16 1986-03-13 Laboratorien Hausmann AG, St. Gallen Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung
US4569836A (en) * 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
EP0330801A1 (en) * 1983-02-08 1989-09-06 Schering Aktiengesellschaft Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
DE3422249A1 (de) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
DE3572440D1 (en) * 1984-06-19 1989-09-28 Basf Ag Gastro-resistant cylindrical pancreatine-microtablets
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5055288A (en) * 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
SU1807606A1 (ru) * 1991-03-29 1995-08-09 Пермский политехнический институт Способ получения анионообменника на основе гидроксида титана
US5234697A (en) * 1992-06-22 1993-08-10 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
EP0585898B1 (en) 1992-09-04 1998-08-05 Mitsubishi Chemical Corporation Process for the production and use of an anion exchange resin
DE4239442C2 (de) * 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
DE19547356A1 (de) * 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
US5906978A (en) * 1996-08-14 1999-05-25 Hemocleanse, Inc. Method for iron delivery to a patient by transfer from dialysate
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
DE10128511A1 (de) * 2001-06-13 2002-12-19 Sebo Gmbh Verwendung eines Phosphatadsorbers gegen Gefäßerkrankungen
JPWO2003053565A1 (ja) 2001-12-21 2005-04-28 室町ケミカル株式会社 リン酸の吸着剤
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens

Also Published As

Publication number Publication date
RU2447933C2 (ru) 2012-04-20
US20120126440A1 (en) 2012-05-24
IL198548A0 (en) 2010-02-17
US8252310B2 (en) 2012-08-28
AU2007331482B2 (en) 2011-04-21
NO342285B1 (no) 2018-04-30
AU2007331482A1 (en) 2008-06-19
CA2671828A1 (en) 2008-06-19
RU2009126614A (ru) 2011-01-20
SI2319804T1 (sl) 2015-01-30
MY151047A (en) 2014-03-31
AR064301A1 (es) 2009-03-25
ES2526171T3 (es) 2015-01-07
HK1133248A1 (en) 2010-03-19
NO20092632L (no) 2009-07-14
TWI465239B (zh) 2014-12-21
PT2319804E (pt) 2014-11-24
NZ576672A (en) 2012-02-24
JP2008150375A (ja) 2008-07-03
WO2008071747A1 (en) 2008-06-19
US20080145410A1 (en) 2008-06-19
CL2007003606A1 (es) 2008-07-18
ECSP099410A (es) 2009-07-31
BRPI0720272A2 (pt) 2014-01-28
CA2671828C (en) 2012-06-19
JP5456969B2 (ja) 2014-04-02
MA30993B1 (fr) 2009-12-01
KR20090094820A (ko) 2009-09-08
PE20081381A1 (es) 2008-11-12
MX2009006307A (es) 2009-06-23
TW200831115A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
TN2009000214A1 (en) Manufacture process
TW200716624A (en) Compounds for modulating TRPV3 function
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MY148299A (en) Iron-carbohydrate complex compounds
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
IN2012DN03883A (enExample)
MX2012006678A (es) Mejoras en la desintegracion y/o degradacion de un articulo para fumar.
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MY160456A (en) Benzodiazepine bromodomain inhibitor
MX2009001835A (es) Resinas de metacrilato para la produccion de lineas de señalizacion vial.
IL208027A0 (en) Methods, compositions, and kits for treating pain and pruritus
MY150292A (en) Process for the preparation of triamides from ammonia and amido-dichlorides
MY147732A (en) Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
TN2012000457A1 (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
UA98299C2 (ru) Новая лекарственная форма рацекадотрила
MX2009004757A (es) Moduladores de regeneracion neuronal.
MY150600A (en) Use of opioid antagonists for treating urinary retention
SG143149A1 (en) Phosphite composition and method for producing the same
MX338441B (es) Uso de 2,3-dihidroxipropil dodecanoato para tratar seborrea.